Physician profile
Puja Mathur
NPI 1366709438
$6,281.40
in general payments reported to CMS, 2019-2025
37 companies · $879 in 2025
The $879 reported for 2025 was more than what a typical Clinical Neurophysiology provider received nationally (typical 2025 total: $435).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $154 · 2021: $638 · 2022: $1,759 · 2023: $1,768 · 2024: $1,084 · 2025: $879.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,731.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,730.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,649.49 | 2021-2025 | |
| Acadia Pharmaceuticals INC | $1,230.14 | 2022-2025 | Nuplazid |
| Neurocrine Biosciences, INC. | $458.17 | 2022-2024 | Ingrezza, Ongentys |
| Ucb, INC. | $396.15 | 2023-2025 | Fintepla, Zilbrysq, Rystiggo |
| Biohaven Pharmaceutical Holding Company Ltd. | $297.87 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $297.69 | 2021-2023 | Austedo |
| Amneal Pharmaceuticals LLC | $179.60 | 2021-2023 | Rytary |
| Argenx US, INC. | $179.35 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
| Allergan, INC. | $144.16 | 2020-2022 | |
| Pfizer INC. | $121.55 | 2023-2025 | |
| Akcea Therapeutics, INC. | $114.32 | 2020 | |
| Corium, LLC | $98.21 | 2022-2023 | Adlarity |
| Sk Life Science, INC. | $98.08 | 2022 | |
| Lilly USA, LLC | $86.34 | 2021-2023 | Emgality |
| Takeda Pharmaceuticals U.S.A., INC. | $83.41 | 2021-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $71.20 | 2021 | |
| Amgen INC. | $70.51 | 2021-2022 | |
| Biogen, INC. | $67.36 | 2022-2025 | Leqembi, Tysabri, Vumerity |
| Novartis Pharmaceuticals Corporation | $65.76 | 2021-2024 | |
| Octapharma USA, INC. | $51.49 | 2022 | |
| Microtransponder, INC. | $50.89 | 2023 | |
| Lundbeck LLC | $47.39 | 2022-2023 | Vyepti |
| Boston Scientific Corporation | $43.48 | 2021-2023 | Wavewriter Alpha Prime 16 |
| Tanabe Pharma America, INC. | $38.73 | 2022-2023 | |
| Avanir Pharmaceuticals, INC. | $38.35 | 2022 | |
| Alexion Pharmaceuticals, INC. | $34.39 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $32.55 | 2023 | Qelbree |
| Csl Behring | $32.36 | 2022 | |
| Eisai INC. | $28.38 | 2025 | |
| Kyowa Kirin, INC. | $28.34 | 2022 | |
| Sumitomo Pharma America, INC. | $28.15 | 2023 | Aptiom |
| Greenwich Biosciences, INC. | $26.19 | 2021 | |
| Livanova USA, INC. | $24.48 | 2021 | |
| Amylyx Pharmaceuticals, INC. | $17.95 | 2023 | Relyvrio |
| Sunovion Pharmaceuticals INC. | $17.35 | 2022 | |
| Mallinckrodt Hospital Products INC. | $16.04 | 2021 | |
| Janssen Pharmaceuticals, INC | $15.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Puja Mathur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.